Cargando…

Is it safe and efficacious to remove central lines in pediatric bone marrow transplant patients with platelets less than 20,000/μl?

BACKGROUND: Patients with tunneled central venous lines (CVL) may develop bloodstream infections which at times are difficult to control without line removal. Concomitant severe thrombocytopenia with platelet transfusion refractoriness is often considered a major contraindication to any procedure in...

Descripción completa

Detalles Bibliográficos
Autores principales: Marwah, Priya, Ramprakash, Stalin, Prasad T R, Sai, Gizhlaryan, Mane, Trivedi, Deepa, Shah, Vaibhav, Chitaliya, Amit, Elizabeth, Sandeep, Agarwal, Rajat Kumar, Dhanya, Rakesh, Faulkner, Lawrence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175805/
https://www.ncbi.nlm.nih.gov/pubmed/35846206
http://dx.doi.org/10.1002/jha2.379
_version_ 1784722527083298816
author Marwah, Priya
Ramprakash, Stalin
Prasad T R, Sai
Gizhlaryan, Mane
Trivedi, Deepa
Shah, Vaibhav
Chitaliya, Amit
Elizabeth, Sandeep
Agarwal, Rajat Kumar
Dhanya, Rakesh
Faulkner, Lawrence
author_facet Marwah, Priya
Ramprakash, Stalin
Prasad T R, Sai
Gizhlaryan, Mane
Trivedi, Deepa
Shah, Vaibhav
Chitaliya, Amit
Elizabeth, Sandeep
Agarwal, Rajat Kumar
Dhanya, Rakesh
Faulkner, Lawrence
author_sort Marwah, Priya
collection PubMed
description BACKGROUND: Patients with tunneled central venous lines (CVL) may develop bloodstream infections which at times are difficult to control without line removal. Concomitant severe thrombocytopenia with platelet transfusion refractoriness is often considered a major contraindication to any procedure involving a major blood vessel. There is very little literature on the clinical risks of tunneled central line removal in febrile pancytopenia patients. PROCEDURE: We analyzed complications and outcomes in all our patients, a total of 52, who underwent CVL removal with platelets <20,000/μl. RESULTS: CVL removal was done on a median day of 17.5 with 47 of the 52 patients never having achieved platelets engraftment prior to line removal. No bleeding episodes or unplanned transfusions could be associated with CVL removal. No other complications were also reported. All patients had time to hemostasis within 5 min of catheter removal. Removal of CVL under local anesthesia remained complication‐free even at platelet counts less than 20,000/ul. A total of 31 patients were febrile at the time of CVL removal, of which 17 became afebrile within 2 days. We found no difference in defervescence when comparing those whose antibiotic therapy was changed/escalated versus those in whom it was not. CONCLUSION: Our findings suggest that central lines can be safely removed with platelet counts less than 20,000/ul and that this may result in enhanced bloodstream infection control. This might be particularly relevant to neutropenic patients in this day and age of multidrug‐resistant organism emergence and paucity of new effective antibiotics.
format Online
Article
Text
id pubmed-9175805
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91758052022-07-14 Is it safe and efficacious to remove central lines in pediatric bone marrow transplant patients with platelets less than 20,000/μl? Marwah, Priya Ramprakash, Stalin Prasad T R, Sai Gizhlaryan, Mane Trivedi, Deepa Shah, Vaibhav Chitaliya, Amit Elizabeth, Sandeep Agarwal, Rajat Kumar Dhanya, Rakesh Faulkner, Lawrence EJHaem BMT and Cellular Therapy BACKGROUND: Patients with tunneled central venous lines (CVL) may develop bloodstream infections which at times are difficult to control without line removal. Concomitant severe thrombocytopenia with platelet transfusion refractoriness is often considered a major contraindication to any procedure involving a major blood vessel. There is very little literature on the clinical risks of tunneled central line removal in febrile pancytopenia patients. PROCEDURE: We analyzed complications and outcomes in all our patients, a total of 52, who underwent CVL removal with platelets <20,000/μl. RESULTS: CVL removal was done on a median day of 17.5 with 47 of the 52 patients never having achieved platelets engraftment prior to line removal. No bleeding episodes or unplanned transfusions could be associated with CVL removal. No other complications were also reported. All patients had time to hemostasis within 5 min of catheter removal. Removal of CVL under local anesthesia remained complication‐free even at platelet counts less than 20,000/ul. A total of 31 patients were febrile at the time of CVL removal, of which 17 became afebrile within 2 days. We found no difference in defervescence when comparing those whose antibiotic therapy was changed/escalated versus those in whom it was not. CONCLUSION: Our findings suggest that central lines can be safely removed with platelet counts less than 20,000/ul and that this may result in enhanced bloodstream infection control. This might be particularly relevant to neutropenic patients in this day and age of multidrug‐resistant organism emergence and paucity of new effective antibiotics. John Wiley and Sons Inc. 2022-01-15 /pmc/articles/PMC9175805/ /pubmed/35846206 http://dx.doi.org/10.1002/jha2.379 Text en © 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle BMT and Cellular Therapy
Marwah, Priya
Ramprakash, Stalin
Prasad T R, Sai
Gizhlaryan, Mane
Trivedi, Deepa
Shah, Vaibhav
Chitaliya, Amit
Elizabeth, Sandeep
Agarwal, Rajat Kumar
Dhanya, Rakesh
Faulkner, Lawrence
Is it safe and efficacious to remove central lines in pediatric bone marrow transplant patients with platelets less than 20,000/μl?
title Is it safe and efficacious to remove central lines in pediatric bone marrow transplant patients with platelets less than 20,000/μl?
title_full Is it safe and efficacious to remove central lines in pediatric bone marrow transplant patients with platelets less than 20,000/μl?
title_fullStr Is it safe and efficacious to remove central lines in pediatric bone marrow transplant patients with platelets less than 20,000/μl?
title_full_unstemmed Is it safe and efficacious to remove central lines in pediatric bone marrow transplant patients with platelets less than 20,000/μl?
title_short Is it safe and efficacious to remove central lines in pediatric bone marrow transplant patients with platelets less than 20,000/μl?
title_sort is it safe and efficacious to remove central lines in pediatric bone marrow transplant patients with platelets less than 20,000/μl?
topic BMT and Cellular Therapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175805/
https://www.ncbi.nlm.nih.gov/pubmed/35846206
http://dx.doi.org/10.1002/jha2.379
work_keys_str_mv AT marwahpriya isitsafeandefficacioustoremovecentrallinesinpediatricbonemarrowtransplantpatientswithplateletslessthan20000ml
AT ramprakashstalin isitsafeandefficacioustoremovecentrallinesinpediatricbonemarrowtransplantpatientswithplateletslessthan20000ml
AT prasadtrsai isitsafeandefficacioustoremovecentrallinesinpediatricbonemarrowtransplantpatientswithplateletslessthan20000ml
AT gizhlaryanmane isitsafeandefficacioustoremovecentrallinesinpediatricbonemarrowtransplantpatientswithplateletslessthan20000ml
AT trivedideepa isitsafeandefficacioustoremovecentrallinesinpediatricbonemarrowtransplantpatientswithplateletslessthan20000ml
AT shahvaibhav isitsafeandefficacioustoremovecentrallinesinpediatricbonemarrowtransplantpatientswithplateletslessthan20000ml
AT chitaliyaamit isitsafeandefficacioustoremovecentrallinesinpediatricbonemarrowtransplantpatientswithplateletslessthan20000ml
AT elizabethsandeep isitsafeandefficacioustoremovecentrallinesinpediatricbonemarrowtransplantpatientswithplateletslessthan20000ml
AT agarwalrajatkumar isitsafeandefficacioustoremovecentrallinesinpediatricbonemarrowtransplantpatientswithplateletslessthan20000ml
AT dhanyarakesh isitsafeandefficacioustoremovecentrallinesinpediatricbonemarrowtransplantpatientswithplateletslessthan20000ml
AT faulknerlawrence isitsafeandefficacioustoremovecentrallinesinpediatricbonemarrowtransplantpatientswithplateletslessthan20000ml